Henderik W Frijlink

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 23

Top Venues

Pharmaceutics

International journal of chronic obstructive pulmonary disease

Expert review of vaccines

Pharmaceuticals (Basel, Switzerland)

University of Groningen

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Groningen Sep 01 2016

Netherlands

Scientific director :: Groningen Research Institute of Pharmacy

University of Groningen Jan 01 1998

Netherlands

Professor and chairman :: Pharmaceutical Technology and Biopharmacy

Publications

Primawan Putra Nugrahadi, Wouter L J Hinrichs, Henderik W Frijlink, Christian Schöneich, Christina Avanti
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics 15 (3) (2023)
Renée S van der Kooij, Martin Beukema, Anke L W Huckriede, Johan Zuidema, Rob Steendam, Henderik W Frijlink, Wouter L J Hinrichs
A Single Injection with Sustained-Release Microspheres and a Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG Antibody Response in Mice. Pharmaceutics 15 (2) (2023)
Renée S van der Kooij, Martin Beukema, Anke L W Huckriede, Johan Zuidema, Rob Steendam, Henderik W Frijlink, Wouter L J Hinrichs
A Single Injection with Sustained-Release Microspheres and a Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG Antibody Response in Mice. Pharmaceutics 15 (2) (2023)
Primawan Putra Nugrahadi, Wouter L J Hinrichs, Henderik W Frijlink, Christian Schöneich, Christina Avanti
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics 15 (3) (2023)
Primawan Putra Nugrahadi, Wouter L J Hinrichs, Henderik W Frijlink, Christian Schöneich, Christina Avanti
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics 15 (3) (2023)
Renée S van der Kooij, Martin Beukema, Anke L W Huckriede, Johan Zuidema, Rob Steendam, Henderik W Frijlink, Wouter L J Hinrichs
A Single Injection with Sustained-Release Microspheres and a Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG Antibody Response in Mice. Pharmaceutics 15 (2) (2023)
Rick Heida, Paul Hagedoorn, Melle C van Meel, Jurrie E R Prins, Frederike S Simonis, Renate Akkerman, Anke L W Huckriede, Henderik W Frijlink, Anne H de Boer, Wouter L J Hinrichs
Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice. Pharmaceutics 15 (7) (2023)
Aisha A Ahmed, Antonius Timotheus Otten, Bahez Gareb, Judith E Huijmans, Anko C Eissens, Ateequr Rehman, Gerard Dijkstra, Jos G W Kosterink, Henderik W Frijlink, Reinout C A Schellekens
Capsules with Ileocolonic-Targeted Release of Vitamin B 2 , B 3 , and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process. Pharmaceutics 15 (5) (2023)
Khanh T T Nguyen, Daan Zillen, Franca F M Heijningen, Kjeld J C van Bommel, Renz J van Ee, Henderik W Frijlink, Wouter L J Hinrichs
Surface Engineering Methods for Powder Bed Printed Tablets to Optimize External Smoothness and Facilitate the Application of Different Coatings. Pharmaceutics 15 (9) (2023)
Rick Heida, Philip A Born, Gabriela Tapia-Calle, Henderik W Frijlink, Anna Salvati, Anke L W Huckriede, Wouter L J Hinrichs
Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro. Pharmaceuticals (Basel, Switzerland) 15 (7) (2022)
Evalyne M Jansen, Henderik W Frijlink, Wouter L J Hinrichs, Mitchel J R Ruigrok
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert opinion on drug delivery 19 (11) (2022)
Herman J Woerdenbag, J Carolina Visser, Marlyn P A M Leferink Op Reinink, Roël R van Orsoy, Anko C Eissens, Paul Hagedoorn, Hilda Dijkstra, Derk P Allersma, Shi W Ng, Oscar S N M Smeets, Henderik W Frijlink
Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets. Pharmaceutics 14 (2) (2022)
Khanh T T Nguyen, Franca F M Heijningen, Daan Zillen, Kjeld J C van Bommel, Renz J van Ee, Henderik W Frijlink, Wouter L J Hinrichs
Formulation of a 3D Printed Biopharmaceutical: The Development of an Alkaline Phosphatase Containing Tablet with Ileo-Colonic Release Profile to Treat Ulcerative Colitis. Pharmaceutics 14 (10) (2022)
Rick Heida, Wouter L J Hinrichs, Henderik W Frijlink
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert review of vaccines (2021)
Renée S van der Kooij, Rob Steendam, Johan Zuidema, Henderik W Frijlink, Wouter L J Hinrichs
Microfluidic Production of Polymeric Core-Shell Microspheres for the Delayed Pulsatile Release of Bovine Serum Albumin as a Model Antigen. Pharmaceutics 13 (11) (2021)
Annemarie Broesder, Julia M E Berends, Sophie M Scheepers, Duong N Nguyen, Henderik W Frijlink, Wouter L J Hinrichs
Ileo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems. Pharmaceutics 13 (5) (2021)
Annemarie Broesder, Said Y Bircan, Anneko B de Waard, Anko C Eissens, Henderik W Frijlink, Wouter L J Hinrichs
Formulation and In Vitro Evaluation of Pellets Containing Sulfasalazine and Caffeine to Verify Ileo-Colonic Drug Delivery. Pharmaceutics 13 (12) (2021)
Yu Tian, Yoshita C Bhide, Herman J Woerdenbag, Anke L W Huckriede, Henderik W Frijlink, Wouter L J Hinrichs, J Carolina Visser
Development of an Orodispersible Film Containing Stabilized Influenza Vaccine. Pharmaceutics 12 (3) (2020)
Imco Sibum, Paul Hagedoorn, Carel O Botterman, Henderik W Frijlink, Floris Grasmeijer
Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility. Pharmaceutics 12 (7) (2020)
Bahez Gareb, Antonius T Otten, Henderik W Frijlink, Gerard Dijkstra, Jos G W Kosterink
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 12 (6) (2020)
Imco Sibum, Paul Hagedoorn, Markus P G Kluitman, Martijn Kloezen, Henderik W Frijlink, Floris Grasmeijer
Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine. Pharmaceutics 12 (1) (2019)
Bahez Gareb, Silke Posthumus, Max Beugeling, Pauline Koopmans, Daan J Touw, Gerard Dijkstra, Jos G W Kosterink, Henderik W Frijlink
Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics 11 (9) (2019)
Rob Janssen, Emiel Fm Wouters, Wim Janssens, Willeke F Daamen, Paul Hagedoorn, Hugo Ajm de Wit, Jef Serré, Ghislaine Gayan-Ramirez, Frits M E Franssen, Niki L Reynaert, Jan H von der Thusen, Henderik W Frijlink
Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale. International journal of chronic obstructive pulmonary disease 14 (2019)

Henderik W Frijlink.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Henderik W Frijlink